Close Menu

Breaking News

The option was exercised under a multiyear contract between T2 Bio and BARDA valued at a total of $69 million if all options are exercised.

The test uses real-time reverse transcription loop-mediated isothermal amplification to detect the SARS-CoV-2 N gene, according to CellSafe.

The company's Eonis assay, which leverages RT-PCR technology, can be used to simultaneously tests for SMA, SCID, and XLA in newborns.

The company said it intends to use proceeds for general corporate purposes, including working capital and refinancing of outstanding indebtedness.

The project, coordinated by Jena University Hospital and expected to run for five years, aims to address resistance mechanisms in Gram-negative pathogens.

The Seattle-based firm has won two grants each worth $1.9 million to develop proximity ligation assays with applications in cytogenetics.

Funding for Fluidigm's assay through NIH's RADx program was increased by approximately $22 million for a total contract value of up to about $34 million.

Applied DNA Sciences previously partnered with Stony Brook University Hospital to validate the test, which received Emergency Use Authorization in May.

The deal enables Genosity to add Olink's proteomics technology with next-generation sequencing readout to its repertoire of services.

The PCR assay is used for the detection of SARS-CoV-2 RNA in anterior nasal swab specimens self-collected at home using the Vo' COVID-19 Test Home Collection Kit.

BillionToOne's assay detects SARS-CoV-2 in samples from nasal, nasopharyngeal, and oropharyngeal swabs and has a testing capacity of 1 million tests per day.

Sema4 will use its genomics testing abilities and Centrellis health intelligence platform to identify eligible patients for Janssen's oncology clinical trials.

The notes are general senior unsecured obligations of Hologic guaranteed by certain domestic subsidiaries and expire on Feb. 15, 2029.

Whole-exome sequencing of 250 parent-offspring trios provided evidence for genetically mediated dysregulation of early neuronal connectivity in cerebral palsy.

The study, involving almost 1.8 million individuals, further found only modest overlap between the genetic underpinnings of left-handedness and ambidexterity.

The strategy promises to offer patients the best possible predictive, preventative, and personalized care underpinned by genome sequencing.

Investigators identified disease-associated histone modifications in the brain that appeared to influence transcription- and chromatin-related processes.

The newly CE-IVD-marked devices are part of the company's DNA/RNA Shield line of sample collection, preservation, and transportation products.

The firm's Nanotrap virus particles provide an alternative to RNA extraction kits and could help improve detection for respiratory viruses, including SARS-CoV-2.

The submission data highlights Parsortix's ability to harvest circulating tumor cells from metastatic breast cancer patient blood samples for downstream analysis. 

Last week, GenomeWeb's readers were most interested in Illumina's definitive acquisition agreement to purchase Grail for $8 billion in cash and stock.

The firm said being able to test asymptomatic people with its Panther Fusion SARS-CoV-2 assay could play an important role in reopening the economy.

Bioinformatics firm M2Gen will analyze whole-exome sequencing and tumor RNA-seq data for the HudsonAlpha genomic lab affiliate.

A portion of patients with life-threatening COVID-19 pneumonia had inborn errors of TLR3- and IRF7-dependent type I IFN immunity.

The genomic test is covered by Medicare for all men with localized prostate cancer being considered for treatment.

Pages

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.